And to be fair, it is true that — after the initial allocation — the smaller shops, each re-allocate the bite-sized bits of the deal’s tranches, and they may spend a few days on the phone, placing the re-allocated sercurities. That may involve some actual salesmanship — some real work.
But up at the top of the tombstone’s lede-table, the co-leads — J.P Morgan, and Banc of America’s Merrill Lynch imprint (as well as the recently added Citigroup) — likely spent only about half of the morning, and part of the afternoon, on Tuesday, making calls. Making calls to place the initial, largest chunks of these two tranches — totalling $2 billion.
Selling Merck paper is truly a no-brainer — one could (almost) literally fax the calls in, and get the sale, just as easily. [I’ll stop short of suggesting that a pack of lemurs could be trained to run the fax machines, and hit auto-dial, here — but see image at right, just the same(!).]
Afterall, Merck is only slightly less-creditworthy than the US government, yet the investor can make about three-quarters of a percent of extra yield, simply by accepting the nearly non-existent default risk presented by a $45 billion public company, which has just under SIX-times (see page 51 of the most recent Merck SEC Form 10-Q: 1/.168 = 5.952) as much unrestricted free equity, as it has debt and on balance-sheet liabilities. Like I said — a no brainer.
From the final prospectus, then — at page S-18:
. . . .The following table shows the underwriting discounts that we will pay to the underwriters in connection with the offering of the notes:
2016 notes | Per note: 0.350%
2021 notes | Per note: 0.450%
Grand Total: $8,150,000. . . .
Expenses associated with this offering to be paid by us, other than underwriting discounts, are estimated to be approximately $1.1 million. . . .
My reaction? Great work — if you can get it — at BofA’s Merrill Lynch, J.P. Morgan and Citi (a subsequent top tier addition to the Merck 2010 debt deal bookrunners). Now, can someone from “Madagascar 2” come collect this lil’ fellow?